Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
Following a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK American Depositary Shares), an increase in the notional allocation of ADSs occurred on August 17, 2012, at a price of $46.33 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: August 17, 2012 (Notification date: August 20, 2012).
- Instrument: GSK American Depositary Shares (ADSs).
- Price: $46.33 per ADS.
- Parties Involved: Dr. M M Slaoui (Director/PDMR) and Dr. K Slaoui (Connected Person).
- Allocation Details: Dr. M M Slaoui received 0 ADSs; Dr. K Slaoui received 4 ADSs.
- Context: The transaction resulted from a revaluation of the cash element within the US Retirement Savings Plan.